tetano
Editor, Senior Moderator
Antimicrob Agents Chemother. 2012 Jun 4. [Epub ahead of print]
Therapeutic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H275Y Neuraminidase Mutation.
Abed Y, Pizzorno A, Boivin G.
Source
Research Center in Infectious Diseases of the CHUQ-CHUL and Laval University, Qu?bec City, Qu?bec, Canada.
Abstract
The therapeutic activity of intramuscular (IM) peramivir was evaluated in mice infected with a recombinant influenza A/WSN/33 virus containing the H275Y neuraminidase (NA) mutation known to confer oseltamivir resistance. Regimens consisted of single (90 mg/kg) or multiple (45 mg/kg daily for 5 days) IM peramivir doses that were initiated 24 h or 48 h post-infection (p.i.). Oral oseltamivir regimen (1 or 10 mg/kg daily for 5 days) was used for comparison. Untreated animals had a mortality rate of 75% and showed a mean weight loss of 16.9 % on day 5 p.i.. When started at 24 h p.i., both peramivir regimens prevented mortality and significantly reduced weight loss (P<0.001) and lung viral titers (LVT) (P<0.001). High dose (10 mg/kg) of oseltamivir initiated at 24 h p.i. also prevented mortality and significantly decreased weight loss (P<0.05) and LVT (P<0.001) compared to the untreated group. By contrast, low dose (1 mg/kg) of oseltamivir did not show any benefits. When started at 48 h p.i., both peramivir regimens prevented mortality and significantly reduced weight loss (P<0.01) and LVT (P<0.001) whereas low dose or high dose oseltamivir regimens had no effect on mortality rates, body weight loss and LVT. Our results show that single dose and multiple dose IM peramivir regimens retain clinical and virological activities against the A/H1N1 H275Y variant despite some reduction in susceptibility when assessed in vitro using enzymatic assays. IM peramivir could constitute an alternative for oseltamivir-resistant A/H1N1 infections although additional studies are warranted to support such recommendation.
PMID:
22664977
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22664977
Therapeutic Activity of Intramuscular Peramivir in Mice Infected with a Recombinant Influenza A/WSN/33 (H1N1) Virus Containing the H275Y Neuraminidase Mutation.
Abed Y, Pizzorno A, Boivin G.
Source
Research Center in Infectious Diseases of the CHUQ-CHUL and Laval University, Qu?bec City, Qu?bec, Canada.
Abstract
The therapeutic activity of intramuscular (IM) peramivir was evaluated in mice infected with a recombinant influenza A/WSN/33 virus containing the H275Y neuraminidase (NA) mutation known to confer oseltamivir resistance. Regimens consisted of single (90 mg/kg) or multiple (45 mg/kg daily for 5 days) IM peramivir doses that were initiated 24 h or 48 h post-infection (p.i.). Oral oseltamivir regimen (1 or 10 mg/kg daily for 5 days) was used for comparison. Untreated animals had a mortality rate of 75% and showed a mean weight loss of 16.9 % on day 5 p.i.. When started at 24 h p.i., both peramivir regimens prevented mortality and significantly reduced weight loss (P<0.001) and lung viral titers (LVT) (P<0.001). High dose (10 mg/kg) of oseltamivir initiated at 24 h p.i. also prevented mortality and significantly decreased weight loss (P<0.05) and LVT (P<0.001) compared to the untreated group. By contrast, low dose (1 mg/kg) of oseltamivir did not show any benefits. When started at 48 h p.i., both peramivir regimens prevented mortality and significantly reduced weight loss (P<0.01) and LVT (P<0.001) whereas low dose or high dose oseltamivir regimens had no effect on mortality rates, body weight loss and LVT. Our results show that single dose and multiple dose IM peramivir regimens retain clinical and virological activities against the A/H1N1 H275Y variant despite some reduction in susceptibility when assessed in vitro using enzymatic assays. IM peramivir could constitute an alternative for oseltamivir-resistant A/H1N1 infections although additional studies are warranted to support such recommendation.
PMID:
22664977
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22664977